Bionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002
Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics designed to harness multi-targeted biology for immune-mediated inflammatory diseases, has announced positive interim results from its ongoing Phase 1 first-in-human clinical study of BYN-002 (TL-001). The investigational long-acting monoclonal antibody targets tumor necrosis factor-like ligand 1A (TL1A) and is being developed for the treatment of inflammatory bowel disease (IBD) and other diseases driven by the TL1A pathway.
The interim findings indicate that BYN-002 has a favorable safety and tolerability profile, an extended pharmacokinetic profile, sustained suppression of its intended molecular target, and encouraging immunogenicity results. These characteristics could support less frequent maintenance dosing and potentially improve treatment convenience for patients with chronic inflammatory conditions.
The company presented the findings in a late-breaking poster at United European Gastroenterology (UEG) Week 2026 in Barcelona, Spain. The poster, titled “BYN-002 (TL-001), A Next-Generation Anti-TL1A Antibody Demonstrating Potent Neutralization, Extended Pharmacokinetics, Durable TL1A Suppression and Favorable Immunogenicity: Interim Phase 1 SAD/MAD Results,” describes interim data from a randomized, double-blind, placebo-controlled Phase 1 study in healthy volunteers.
The clinical trial, registered under ClinicalTrials.gov identifier NCT06867796, is evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of BYN-002. According to Bionyra Pharma, the interim results met all primary objectives of the study, supporting further investigation of the candidate in clinical development.
Extended Pharmacokinetics Could Support Less Frequent Dosing
One of the key findings from the interim Phase 1 study was the extended terminal half-life of BYN-002. In the multiple ascending dose (MAD) cohorts, the antibody demonstrated a terminal half-life ranging from 77.8 to 82.0 days. This prolonged duration in the body could allow the investigational therapy to maintain its biological activity over an extended period following administration.
The company also reported dose-proportional pharmacokinetics, indicating that exposure to BYN-002 increased in a manner consistent with the administered dose across the evaluated range. This finding provides useful information about how the antibody behaves in the body and can help guide dose selection and administration schedules in subsequent clinical studies.
Based on preliminary terminal half-life estimates, Bionyra Pharma believes BYN-002 may have the potential to support maintenance dosing intervals of every three to six months. If confirmed in future trials, such a schedule could offer a meaningful convenience advantage for people requiring long-term treatment for IBD and other TL1A-driven diseases.
However, the proposed dosing interval remains a development hypothesis based on early clinical pharmacokinetic findings. Further studies will be needed to establish the appropriate dose, duration of target suppression, clinical effectiveness, and long-term safety of BYN-002 in patients with inflammatory diseases.
Extended dosing intervals are an important consideration in chronic disease management because treatment often requires sustained control of inflammation over many months or years. Depending on the disease, treatment regimen, and individual patient needs, less frequent administration could reduce the practical burden associated with ongoing therapy.
For patients with IBD, which includes conditions such as Crohn’s disease and ulcerative colitis, maintaining disease control can involve long-term treatment and continued monitoring. An investigational antibody with an extended half-life could potentially provide an additional treatment option if its pharmacological properties translate into sustained clinical benefits.
Sustained Suppression of the TL1A Pathway
Another important finding was the sustained suppression of free soluble TL1A across all dose levels evaluated in the study. Bionyra Pharma reported that free soluble TL1A concentrations remained below the lower limit of quantification, suggesting substantial and durable engagement of the intended target.
TL1A is a signaling molecule involved in inflammatory and immune responses. The pathway has attracted increasing attention in the development of treatments for IBD and other immune-mediated conditions because of its potential role in driving inflammation and contributing to disease processes.
By targeting TL1A with a monoclonal antibody, BYN-002 is designed to interfere with this signaling pathway. The objective is to reduce disease-associated inflammatory activity by inhibiting the biological effects of the target molecule.
The reported suppression of free soluble TL1A provides pharmacodynamic evidence that BYN-002 can affect its intended molecular pathway in humans. Combined with the extended half-life, the finding suggests that the antibody may maintain target suppression for a prolonged period.
Nevertheless, pharmacodynamic activity is distinct from clinical efficacy. Although sustained target suppression is an encouraging early finding, it does not by itself demonstrate that BYN-002 can improve symptoms, induce remission, prevent disease complications, or reduce the need for other treatments in patients with IBD.
Additional clinical trials will need to assess whether the observed molecular effects translate into meaningful improvements in disease activity and patient outcomes. These studies will also help determine how target suppression relates to the duration of clinical response and whether different dosing regimens provide comparable benefits.
Favorable Safety and Tolerability in the Phase 1 Study
The interim findings also indicated that BYN-002 was generally well tolerated among the healthy volunteers evaluated to date. Bionyra Pharma reported no treatment-related serious adverse events, infusion reactions, deaths, or treatment-related discontinuations in the interim analysis.
These observations are relevant to the continued development of the antibody because safety and tolerability are central considerations when assessing investigational biologics, particularly those intended for chronic inflammatory diseases that may require long-term treatment.
The absence of reported treatment-related serious adverse events in the interim dataset is encouraging, but the findings should be interpreted in the context of an early-stage study involving healthy volunteers. Phase 1 trials generally include relatively limited numbers of participants and are not designed to establish the full safety profile of a medicine across a broad patient population.
As clinical development advances, additional data will be needed to characterize potential adverse events, assess the effects of repeated administration, and identify any safety considerations associated with prolonged exposure to the antibody.
Studies involving patients with IBD and other TL1A-driven conditions will also be important because the characteristics of people with active inflammatory disease may differ from those of healthy volunteers. Disease activity, concomitant medications, underlying health conditions, and other factors can influence both treatment response and tolerability.
The company’s ongoing evaluation of BYN-002 will therefore need to establish whether the favorable early safety findings remain consistent as the number of treated participants increases and exposure extends over longer periods.
Immunogenicity Findings Support Further Evaluation
Bionyra Pharma also reported encouraging preliminary findings regarding the immunogenicity of BYN-002. Across the multiple ascending dose cohorts, the reported immunogenicity rate was 9.1%, with anti-drug antibody (ADA) responses observed primarily in the lower-dose cohorts.
Immunogenicity refers to the ability of a therapeutic protein or other biologic medicine to trigger an immune response against itself. In some cases, patients develop antibodies that recognize the administered medicine. These antibodies may have little clinical effect, or they may influence drug exposure, biological activity, safety, or treatment response.
For monoclonal antibodies intended for repeated administration, monitoring ADA responses is an important component of clinical development. The presence of anti-drug antibodies does not automatically mean that a treatment will be ineffective or unsafe. Their significance depends on factors such as antibody levels, persistence, neutralizing activity, and any associated changes in pharmacokinetics or clinical outcomes.
The reported ADA pattern, with responses primarily observed in lower-dose cohorts, provides an initial basis for further assessment. However, the available interim information does not establish why these responses were concentrated in those cohorts or whether they will have any effect on treatment performance.
Future studies will need to characterize the frequency, magnitude, and persistence of ADA responses and determine whether they are associated with changes in drug exposure or target suppression. Additional data will also be necessary to establish whether the observed immunogenicity profile remains consistent during longer-term treatment.
Together with the pharmacokinetic and pharmacodynamic findings, the early immunogenicity results will help inform the design of subsequent trials and the selection of dose levels for further clinical investigation.
BYN-002 Development Strategy for IBD and Other Inflammatory Diseases
Bionyra Pharma is developing BYN-002 as part of its broader strategy to advance next-generation biologics for immune-mediated inflammatory diseases. The company’s approach focuses on the potential of targeted biological mechanisms to address diseases characterized by persistent or dysregulated immune activity.
IBD represents a key area of interest for TL1A-targeted therapies. Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract that can have substantial effects on patients’ daily lives. Symptoms and disease severity vary, and patients may require long-term medical management to control inflammation and maintain remission.
Although existing therapies have improved treatment options for many patients, disease control remains challenging for some individuals. Differences in response, loss of response over time, tolerability concerns, and the need for ongoing treatment continue to create demand for additional therapeutic approaches.
TL1A inhibition is being investigated as a strategy to address inflammatory mechanisms relevant to these conditions. BYN-002’s reported combination of sustained target suppression and extended pharmacokinetics could make it a candidate for further exploration in this treatment area.
The company is also evaluating the potential of BYN-002 in other TL1A-driven diseases. The specific clinical opportunities will depend on further research establishing the relevance of TL1A signaling in individual conditions, as well as the safety and efficacy of the antibody in the populations being studied.
At this stage, BYN-002 remains investigational. The Phase 1 interim results do not establish its effectiveness in treating IBD or any other disease, and additional clinical evidence will be required before its potential role in patient care can be determined.
Company Leadership Highlights the Potential of BYN-002
Frédéric Marrache, MD, PhD, MBA, Chief Executive Officer of Bionyra Pharma, said the interim findings provide evidence that BYN-002 combines potent TL1A pathway inhibition with a pharmacokinetic profile that could enable convenient dosing intervals.
“TL1A has emerged as one of the most important targets in inflammatory bowel disease and other TL1A-driven diseases, and we are excited by the profile emerging from this study and its ability to deliver durable target suppression and improved convenience,” Marrache said.
His comments highlight two central elements of the company’s development strategy: sustained inhibition of the target pathway and the possibility of reducing the frequency of maintenance administration. Both characteristics could be important as the company determines how BYN-002 might fit into the future treatment landscape for chronic inflammatory diseases.
The interim results provide an early clinical foundation for evaluating those possibilities, although their significance will depend on the results of subsequent studies in patients.
Next Steps in Clinical Development
The positive interim Phase 1 findings provide Bionyra Pharma with additional information about the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of BYN-002. The results support continued investigation of the antibody, including further assessment of dosing strategies and its potential application in IBD and other diseases associated with TL1A signaling.
Future clinical development will need to establish whether the prolonged terminal half-life observed in healthy volunteers can support the proposed maintenance dosing intervals while maintaining adequate target suppression. Investigators will also need to evaluate clinical efficacy, long-term safety, and immunogenicity in relevant patient populations.
The progression from healthy-volunteer studies to patient trials will be particularly important in determining whether BYN-002 can deliver benefits beyond measurable pharmacological activity. Clinical studies will need to assess disease-specific outcomes and establish the appropriate balance between dose, duration of effect, tolerability, and treatment convenience.
For now, the interim findings offer encouraging early evidence for Bionyra Pharma’s long-acting anti-TL1A antibody. The combination of a terminal half-life of approximately 78 to 82 days in multiple-dose cohorts, sustained suppression of free soluble TL1A, favorable preliminary tolerability, and a reported immunogenicity rate of 9.1% provides a basis for continued development.
The company presented the complete interim findings in its late-breaking poster at UEG Week 2026 in Barcelona. The poster is available at the following link:
Full Phase 1 poster: BYN-002 (TL-001) Interim SAD/MAD Results — UEG Week 2026 (PDF)
As the clinical program advances, additional data will determine whether BYN-002’s pharmacological profile translates into sustained disease control and a practical, less frequent dosing schedule for patients with IBD and other TL1A-driven inflammatory diseases.
About BYN-002 and BYN-003
BYN-002 (TL-001) is a humanized anti-TL1A monoclonal antibody with engineered Fc fragment for extended half-life. BYN-002 (TL-001) is part of Bionyra’s broader TL1A franchise, which also includes BYN-003 (TL-003), a next-generation TL1A×IL-23p19 bispecific antibody designed to address multiple inflammatory pathways simultaneously. Together, these programs reflect Bionyra’s strategy of advancing long-acting antibodies, multispecific biologics and combination approaches capable of delivering deeper efficacy, greater durability and improved convenience for patients with immune-mediated inflammatory diseases.
Bionyra licensed BYN-002 and BYN-003 from TrueLab Biopharmaceutical1and holds exclusive worldwide rights outside Greater China.
About Bionyra Pharma
Bionyra Pharma is a clinical-stage biopharmaceutical company pioneering next-generation biologics for immune-mediated inflammatory diseases. The company develops long-acting antibodies, multispecific biologics and combination approaches designed to unlock the full potential of multi-targeted biology with the goal of achieving deeper efficacy, greater durability and improved convenience for patients. Bionyra’s pipeline spans Type 2 inflammation, inflammatory bowel disease and adjacent immune-mediated diseases and includes clinical-stage IL-25 and TL1A programs as well as next-generation multispecific and combination candidates.